06.29.26 -- Insights Into How Sponsors Search Today For CDMOs

The ADC industry is expanding to supply targeted treatments to support unmet need and patient demand. To succeed, ADC developers must account for the manufacturing complexity.

Complex biologics require flexible development, advanced analytics, and quality by design. Learn how collaborative bioprocessing reduces risk, enables efficient scale‑up, and supports success.

By working with a single supplier that can handle the entire manufacturing value chain, companies can reduce risk, improve flexibility, and accelerate their time to market.

Assimilate how a large manufacturing client helped to focus on their core business with a solution that transitioned approximately 60% of the workforce and capitalized on the initial training investment.

Peter Skals, Head of Global Sustainability, shares how the company is integrating its climate and ESG strategy while simultaneously expanding its CDMO network and reducing its CO₂ footprint.

Leveraging early-stage collaborations and flexible delivery systems can help navigate complex regulatory landscapes while accelerating the delivery of safe, self-administered injectable therapies.

Advances in sustained-release drug delivery could improve efficiency and consistency in drug release, manifesting real-life advantages for patients in the form of enhanced accessibility and compliance.

Advances in synthesis, enzymatic ligation, and purification are reshaping oligonucleotide manufacturing, improving scalability, sustainability, and complexity from research to production.

Partner supporting advanced veterinary biologics with flexible capacity, technical depth, and end‑to‑end capabilities spanning vaccines, recombinant proteins, antibodies, and next‑generation therapies.

Explore how advanced scale-up methodologies and real-time analytical technologies strengthen both drug substance and drug product manufacturing by enabling process understanding.

Integrating advanced digitalization solutions and prioritizing data security can accelerate drug development while reducing costs and ensuring consistency across a global network.

See a structured approach to optimizing and scaling plasmid DNA production using E. coli, with insights into key growth parameters, benchtop feasibility, and pilot-scale performance.

Purpose‑built for modern injectable drug delivery, we integrate advanced aseptic filling, in‑line quality, and capacity to support complex products.